In Oct 2007, the FDA declared the labeling for all PDE5 inhibitors, which include tadalafil, demands a additional distinguished warning with the likely threat of sudden Listening to decline as the result of post-promoting reports of momentary deafness linked to use of PDE5 inhibitors.[19] Some st